Department of Transfusion Medicine, The University of Tokyo, Tokyo, Japan.
Transfusion. 2010 May;50(5):1126-30. doi: 10.1111/j.1537-2995.2009.02537.x. Epub 2009 Dec 18.
The involvement of the human platelet antigen (HPA)-15 system in neonatal alloimmune thrombocytopenia (NAIT) has been reported in various populations, but not in the Japanese population. In Japan, the mixed passive hemagglutination assay (MPHA) is used for detection of HPA alloantibodies. However, most of the reported cases of HPA-15 incompatibility are based on the monoclonal antibody immobilization of platelet antigen (MAIPA) assay or immunoprecipitation; thus there is a possibility that HPA-15 alloantibodies are not efficiently detected by the MPHA, and currently, the causative antibody is not detectable in approximately half of the suspected NAIT cases in Japan.
We examined the sera of mothers from NAIT cases, previously with undetected HPA antibodies by MPHA, using the MAIPA technique. Sera from 90 mothers of suspected NAIT were tested by MAIPA for the presence of anti-HPA-15 alloantibodies.
Anti-HPA-15b was detected in one case. This case was a mother in the first pregnancy diagnosed as hydatid mole-coexisting fetus, and the baby was born with suspected NAIT. The familial analysis revealed compatibility of HPA-15 genotype between the mother and the baby (both HPA-15a/a), but incompatibility with the paternal one (HPA-15a/b). The hydatid mole's tissue was genotyped as HPA-15b positive. Besides anti-HPA-15b, maternal sera contain strong HLA Class I antibody
Here we reported the first case of anti-HPA-15 in Japan. Alloimmunization against the hydatid mole seems to be responsible for the production of HPA-15b alloantibody. This antibody, however, did not apparently involve in the development of NAIT of the newborn, the coexisting anti-HLA Class I being the possible cause.
人类血小板抗原(HPA)-15 系统在新生儿同种免疫性血小板减少症(NAIT)中的作用已在不同人群中报道,但在日本人群中尚未报道。在日本,混合被动血凝试验(MPHA)用于检测 HPA 同种抗体。然而,大多数报道的 HPA-15 不相容性病例是基于血小板抗原的单克隆抗体固定化(MAIPA)检测或免疫沉淀;因此,HPA-15 同种抗体可能不能通过 MPHA 有效检测,目前,在日本大约一半的疑似 NAIT 病例中无法检测到致病抗体。
我们使用 MAIPA 技术检测了先前通过 MPHA 检测不出 HPA 抗体的 NAIT 病例母亲的血清。我们用 MAIPA 检测了 90 例疑似 NAIT 母亲的血清中是否存在抗-HPA-15 同种抗体。
在一例中检测到抗-HPA-15b。该病例是一位被诊断为先兆性葡萄胎合并胎儿的第一胎母亲,婴儿出生时疑似患有 NAIT。家族分析显示母亲和婴儿的 HPA-15 基因型相容(均为 HPA-15a/a),但与父亲的不相容(HPA-15a/b)。葡萄胎组织的 HPA-15 基因型为阳性。除了抗-HPA-15b,母体血清还含有强 HLA Ⅰ类抗体。
我们在此报告了日本首例抗-HPA-15 病例。针对葡萄胎的同种免疫似乎是产生 HPA-15b 同种抗体的原因。然而,这种抗体显然没有参与新生儿 NAIT 的发生,可能是共存的 HLA Ⅰ类抗体导致的。